J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jafron Biomedical Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Total Liabilities & Equity
ÂĄ5.5B
CAGR 3-Years
7%
CAGR 5-Years
20%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Total Liabilities & Equity
ÂĄ2.6B
CAGR 3-Years
63%
CAGR 5-Years
51%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Total Liabilities & Equity
ÂĄ15.6B
CAGR 3-Years
9%
CAGR 5-Years
16%
CAGR 10-Years
22%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Total Liabilities & Equity
ÂĄ60.6B
CAGR 3-Years
21%
CAGR 5-Years
21%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Total Liabilities & Equity
ÂĄ25.3B
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
22%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Total Liabilities & Equity
ÂĄ25.3B
CAGR 3-Years
38%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
5.5B CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Total Liabilities & Equity amounts to 5.5B CNY.

What is Jafron Biomedical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
20%

Over the last year, the Total Liabilities & Equity growth was -3%. The average annual Total Liabilities & Equity growth rates for Jafron Biomedical Co Ltd have been 7% over the past three years , 20% over the past five years .

Back to Top